{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,5]],"date-time":"2026-10-05T06:25:12Z","timestamp":1791181512796,"version":"4.1.0"},"reference-count":28,"publisher":"American Association for Cancer Research (AACR)","issue":"1","content-domain":{"domain":["aacrjournals.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2012,1,1]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The relative timing of genetic alterations that contribute to follicular lymphoma remains unknown. We analyzed a donor\u2013recipient pair who both developed grade 2\/3A follicular lymphoma 7 years after allogeneic transplantation and donor lymphocyte infusions. Both patients harbored identical BCL2\/IGH rearrangements also present in 1 in 2,000 cells in the donor lymphocyte infusion, and the same V(D)J rearrangement, which underwent somatic hypermutation both before and after clonal divergence. Exome sequencing of both follicular lymphomas identified 15 shared mutations, of which 14 (including alterations in EP300 and KLHL6) were recovered from the donor lymphocyte infusion by ultra-deep sequencing (average read coverage, 361,723), indicating acquisition at least 7 years before clinical presentation. Six additional mutations were present in only one follicular lymphoma and not the donor lymphocyte infusion, including an ARID1A premature stop, indicating later acquisition during clonal divergence. Thus, ultrasensitive sequencing can map clonal evolution within rare subpopulations during human lymphomagenesis in vivo.<\/jats:p>\n                  <jats:p>Significance: For the first time, we define the molecular ontogeny of follicular lymphoma during clonal evolution in vivo. By using ultrasensitive mutation detection, we mapped the time-course of somatic alterations after passage of a malignant ancestor by hematopoietic cell transplantation. Cancer Discovery; 2(1); 47\u201355. \u00a92011 AACR.<\/jats:p>\n                  <jats:p>This article is highlighted in the In This Issue feature, p. 1<\/jats:p>","DOI":"10.1158\/2159-8290.cd-11-0208","type":"journal-article","created":{"date-parts":[[2011,12,12]],"date-time":"2011-12-12T22:56:45Z","timestamp":1323730605000},"page":"47-55","update-policy":"https:\/\/doi.org\/10.1158\/crossmark_policy","source":"Crossref","is-referenced-by-count":98,"title":["Molecular Ontogeny of Donor-Derived Follicular Lymphomas Occurring after Hematopoietic Cell Transplantation"],"prefix":"10.1158","volume":"2","author":[{"given":"Oliver","family":"Weigert","sequence":"first","affiliation":[{"name":"Authors' Affiliations: Departments of 1Medical Oncology and 2Biostatistics and Computational Biology, and 3Microarray Core, Dana-Farber Cancer Institute and Harvard Medical School, Boston; 4Department of Pathology, Brigham and Women's Hospital, Boston; and 5Infinity Pharmaceuticals, Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nadja","family":"Kopp","sequence":"additional","affiliation":[{"name":"Authors' Affiliations: Departments of 1Medical Oncology and 2Biostatistics and Computational Biology, and 3Microarray Core, Dana-Farber Cancer Institute and Harvard Medical School, Boston; 4Department of Pathology, Brigham and Women's Hospital, Boston; and 5Infinity Pharmaceuticals, Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew A.","family":"Lane","sequence":"additional","affiliation":[{"name":"Authors' Affiliations: Departments of 1Medical Oncology and 2Biostatistics and Computational Biology, and 3Microarray Core, Dana-Farber Cancer Institute and Harvard Medical School, Boston; 4Department of Pathology, Brigham and Women's Hospital, Boston; and 5Infinity Pharmaceuticals, Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akinori","family":"Yoda","sequence":"additional","affiliation":[{"name":"Authors' Affiliations: Departments of 1Medical Oncology and 2Biostatistics and Computational Biology, and 3Microarray Core, Dana-Farber Cancer Institute and Harvard Medical School, Boston; 4Department of Pathology, Brigham and Women's Hospital, Boston; and 5Infinity Pharmaceuticals, Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suzanne E.","family":"Dahlberg","sequence":"additional","affiliation":[{"name":"Authors' Affiliations: Departments of 1Medical Oncology and 2Biostatistics and Computational Biology, and 3Microarray Core, Dana-Farber Cancer Institute and Harvard Medical School, Boston; 4Department of Pathology, Brigham and Women's Hospital, Boston; and 5Infinity Pharmaceuticals, Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna","family":"Neuberg","sequence":"additional","affiliation":[{"name":"Authors' Affiliations: Departments of 1Medical Oncology and 2Biostatistics and Computational Biology, and 3Microarray Core, Dana-Farber Cancer Institute and Harvard Medical School, Boston; 4Department of Pathology, Brigham and Women's Hospital, Boston; and 5Infinity Pharmaceuticals, Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anita Y.","family":"Bahar","sequence":"additional","affiliation":[{"name":"Authors' Affiliations: Departments of 1Medical Oncology and 2Biostatistics and Computational Biology, and 3Microarray Core, Dana-Farber Cancer Institute and Harvard Medical School, Boston; 4Department of Pathology, Brigham and Women's Hospital, Boston; and 5Infinity Pharmaceuticals, Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bjoern","family":"Chapuy","sequence":"additional","affiliation":[{"name":"Authors' Affiliations: Departments of 1Medical Oncology and 2Biostatistics and Computational Biology, and 3Microarray Core, Dana-Farber Cancer Institute and Harvard Medical School, Boston; 4Department of Pathology, Brigham and Women's Hospital, Boston; and 5Infinity Pharmaceuticals, Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffery L.","family":"Kutok","sequence":"additional","affiliation":[{"name":"Authors' Affiliations: Departments of 1Medical Oncology and 2Biostatistics and Computational Biology, and 3Microarray Core, Dana-Farber Cancer Institute and Harvard Medical School, Boston; 4Department of Pathology, Brigham and Women's Hospital, Boston; and 5Infinity Pharmaceuticals, Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janina A.","family":"Longtine","sequence":"additional","affiliation":[{"name":"Authors' Affiliations: Departments of 1Medical Oncology and 2Biostatistics and Computational Biology, and 3Microarray Core, Dana-Farber Cancer Institute and Harvard Medical School, Boston; 4Department of Pathology, Brigham and Women's Hospital, Boston; and 5Infinity Pharmaceuticals, Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank C.","family":"Kuo","sequence":"additional","affiliation":[{"name":"Authors' Affiliations: Departments of 1Medical Oncology and 2Biostatistics and Computational Biology, and 3Microarray Core, Dana-Farber Cancer Institute and Harvard Medical School, Boston; 4Department of Pathology, Brigham and Women's Hospital, Boston; and 5Infinity Pharmaceuticals, Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Terry","family":"Haley","sequence":"additional","affiliation":[{"name":"Authors' Affiliations: Departments of 1Medical Oncology and 2Biostatistics and Computational Biology, and 3Microarray Core, Dana-Farber Cancer Institute and Harvard Medical School, Boston; 4Department of Pathology, Brigham and Women's Hospital, Boston; and 5Infinity Pharmaceuticals, Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maura","family":"Salois","sequence":"additional","affiliation":[{"name":"Authors' Affiliations: Departments of 1Medical Oncology and 2Biostatistics and Computational Biology, and 3Microarray Core, Dana-Farber Cancer Institute and Harvard Medical School, Boston; 4Department of Pathology, Brigham and Women's Hospital, Boston; and 5Infinity Pharmaceuticals, Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Timothy J.","family":"Sullivan","sequence":"additional","affiliation":[{"name":"Authors' Affiliations: Departments of 1Medical Oncology and 2Biostatistics and Computational Biology, and 3Microarray Core, Dana-Farber Cancer Institute and Harvard Medical School, Boston; 4Department of Pathology, Brigham and Women's Hospital, Boston; and 5Infinity Pharmaceuticals, Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David C.","family":"Fisher","sequence":"additional","affiliation":[{"name":"Authors' Affiliations: Departments of 1Medical Oncology and 2Biostatistics and Computational Biology, and 3Microarray Core, Dana-Farber Cancer Institute and Harvard Medical School, Boston; 4Department of Pathology, Brigham and Women's Hospital, Boston; and 5Infinity Pharmaceuticals, Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edward A.","family":"Fox","sequence":"additional","affiliation":[{"name":"Authors' Affiliations: Departments of 1Medical Oncology and 2Biostatistics and Computational Biology, and 3Microarray Core, Dana-Farber Cancer Institute and Harvard Medical School, Boston; 4Department of Pathology, Brigham and Women's Hospital, Boston; and 5Infinity Pharmaceuticals, Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott J.","family":"Rodig","sequence":"additional","affiliation":[{"name":"Authors' Affiliations: Departments of 1Medical Oncology and 2Biostatistics and Computational Biology, and 3Microarray Core, Dana-Farber Cancer Institute and Harvard Medical School, Boston; 4Department of Pathology, Brigham and Women's Hospital, Boston; and 5Infinity Pharmaceuticals, Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph H.","family":"Antin","sequence":"additional","affiliation":[{"name":"Authors' Affiliations: Departments of 1Medical Oncology and 2Biostatistics and Computational Biology, and 3Microarray Core, Dana-Farber Cancer Institute and Harvard Medical School, Boston; 4Department of Pathology, Brigham and Women's Hospital, Boston; and 5Infinity Pharmaceuticals, Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Weinstock","sequence":"additional","affiliation":[{"name":"Authors' Affiliations: Departments of 1Medical Oncology and 2Biostatistics and Computational Biology, and 3Microarray Core, Dana-Farber Cancer Institute and Harvard Medical School, Boston; 4Department of Pathology, Brigham and Women's Hospital, Boston; and 5Infinity Pharmaceuticals, Cambridge, Massachusetts"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1086","published-online":{"date-parts":[[2012,1,12]]},"reference":[{"key":"2022060622422616400_bib1","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1023\/A:1008265532487","article-title":"Epidemiology of the non-Hodgkin's lymphomas: distributions of the major subtypes differ by geographic locations. Non-Hodgkin's Lymphoma Classification Project","volume":"9","author":"Anderson","year":"1998","journal-title":"Ann Oncol"},{"key":"2022060622422616400_bib2","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1182\/blood-2003-12-4434","article-title":"Follicular lymphoma international prognostic index","volume":"104","author":"Solal-Celigny","year":"2004","journal-title":"Blood"},{"key":"2022060622422616400_bib3","first-page":"220","article-title":"Follicular lymphoma","volume-title":"WHO classification of tumours of haematopoietic and lymphoid tissues","author":"Harris","year":"2008","edition":"4th ed."},{"key":"2022060622422616400_bib4","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1200\/JCO.2001.19.2.420","article-title":"Frequency of the Bcl-2\/IgH rearrangement in normal individuals: implications for the monitoring of disease in patients with follicular lymphoma","volume":"19","author":"Summers","year":"2001","journal-title":"J Clin Oncol"},{"key":"2022060622422616400_bib5","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1084\/jem.20061292","article-title":"Follicular lymphoma-like B cells in healthy individuals: a novel intermediate step in early lymphomagenesis","volume":"203","author":"Roulland","year":"2006","journal-title":"J Exp Med"},{"key":"2022060622422616400_bib6","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1056\/NEJMcibr067155","article-title":"A closer look at follicular lymphoma","volume":"356","author":"Staudt","year":"2007","journal-title":"N Engl J Med"},{"key":"2022060622422616400_bib7","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1038\/nature09730","article-title":"Inactivating mutations of acetyltransferase genes in B-cell lymphoma","volume":"471","author":"Pasqualucci","year":"2011","journal-title":"Nature"},{"key":"2022060622422616400_bib8","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/ng.518","article-title":"Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin","volume":"42","author":"Morin","year":"2010","journal-title":"Nat Genet"},{"key":"2022060622422616400_bib9","doi-asserted-by":"crossref","first-page":"9166","DOI":"10.1158\/0008-5472.CAN-10-2460","article-title":"Acquired TNFRSF14 mutations in follicular lymphoma are associated with worse prognosis","volume":"70","author":"Cheung","year":"2010","journal-title":"Cancer Res"},{"key":"2022060622422616400_bib10","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/nature10351","article-title":"Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma","volume":"476","author":"Morin","year":"2011","journal-title":"Nature"},{"key":"2022060622422616400_bib11","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1016\/j.bbmt.2006.01.006","article-title":"Evidence of donor-derived hematologic malignancies after hematopoietic stem cell transplantation","volume":"12","author":"Sala-Torra","year":"2006","journal-title":"Biol Blood Marrow Transplant"},{"key":"2022060622422616400_bib12","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1016\/j.cell.2008.10.035","article-title":"Human chromosomal translocations at CpG sites and a theoretical basis for their lineage and stage specificity","volume":"135","author":"Tsai","year":"2008","journal-title":"Cell"},{"key":"2022060622422616400_bib13","doi-asserted-by":"crossref","first-page":"2257","DOI":"10.1038\/sj.leu.2403202","article-title":"Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936","volume":"17","author":"van Dongen","year":"2003","journal-title":"Leukemia"},{"key":"2022060622422616400_bib14","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1182\/blood.V79.1.229.229","article-title":"Frequent incidence of somatic mutations in translocated BCL2 oncogenes of non-Hodgkin's lymphomas","volume":"79","author":"Tanaka","year":"1992","journal-title":"Blood"},{"key":"2022060622422616400_bib15","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nature10113","article-title":"Whole-genome sequencing identifies recurrent mutations in chronic lymphocytic leukaemia","volume":"475","author":"Puente","year":"2011","journal-title":"Nature"},{"key":"2022060622422616400_bib16","doi-asserted-by":"crossref","first-page":"D945","DOI":"10.1093\/nar\/gkq929","article-title":"COSMIC: mining complete cancer genomes in the Catalogue of Somatic Mutations in Cancer","volume":"39","author":"Forbes","year":"2011","journal-title":"Nucleic Acids Res"},{"key":"2022060622422616400_bib17","doi-asserted-by":"crossref","first-page":"2298","DOI":"10.1182\/blood-2008-08-174953","article-title":"Regions of acquired uniparental disomy at diagnosis of follicular lymphoma are associated with both overall survival and risk of transformation","volume":"113","author":"O'Shea","year":"2009","journal-title":"Blood"},{"key":"2022060622422616400_bib18","doi-asserted-by":"crossref","first-page":"3015","DOI":"10.1093\/emboj\/cdg293","article-title":"The B cell-specific major raft protein, Raftlin, is necessary for the integrity of lipid raft and BCR signal transduction","volume":"22","author":"Saeki","year":"2003","journal-title":"EMBO J"},{"key":"2022060622422616400_bib19","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/nature07485","article-title":"DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome","volume":"456","author":"Ley","year":"2008","journal-title":"Nature"},{"key":"2022060622422616400_bib20","doi-asserted-by":"crossref","first-page":"e27","DOI":"10.1182\/blood-2010-07-293332","article-title":"RNA-seq analysis of 2 closely related leukemia clones that differ in their self-renewal capacity","volume":"117","author":"Wilhelm","year":"2011","journal-title":"Blood"},{"key":"2022060622422616400_bib21","doi-asserted-by":"crossref","first-page":"8531","DOI":"10.1128\/MCB.25.19.8531-8540.2005","article-title":"The BTB-kelch protein KLHL6 is involved in B-lymphocyte antigen receptor signaling and germinal center formation","volume":"25","author":"Kroll","year":"2005","journal-title":"Mol Cell Biol"},{"key":"2022060622422616400_bib22","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/nature10351","article-title":"Frequent mutation of histone-modifying genes in non-Hodgkin lymphoma","volume":"476","author":"Morin","year":"2011","journal-title":"Nature"},{"key":"2022060622422616400_bib23","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1056\/NEJMoa1008433","article-title":"ARID1A mutations in endometriosis-associated ovarian carcinomas","volume":"363","author":"Wiegand","year":"2010","journal-title":"N Engl J Med"},{"key":"2022060622422616400_bib24","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1126\/science.1196333","article-title":"Frequent mutations of chromatin remodeling gene ARID1A in ovarian clear cell carcinoma","volume":"330","author":"Jones","year":"2010","journal-title":"Science"},{"key":"2022060622422616400_bib25","doi-asserted-by":"crossref","first-page":"e629","DOI":"10.1200\/JCO.2010.29.8992","article-title":"Mantle cell lymphoma 12 years after allogeneic bone marrow transplantation occurring simultaneously in recipient and donor","volume":"28","author":"Christian","year":"2010","journal-title":"J Clin Oncol"},{"key":"2022060622422616400_bib26","doi-asserted-by":"crossref","first-page":"2159","DOI":"10.1056\/NEJMoa041869","article-title":"Prediction of survival in follicular lymphoma based on molecular features of tumor-infiltrating immune cells","volume":"351","author":"Dave","year":"2004","journal-title":"N Engl J Med"},{"key":"2022060622422616400_bib27","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1038\/sj.leu.2404586","article-title":"Analysis of minimal residual disease by Ig\/TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data","volume":"21","author":"van der Velden","year":"2007","journal-title":"Leukemia"},{"key":"2022060622422616400_bib28","first-page":"365","article-title":"Primer3 on the WWW for general users and for biologist programmers","volume":"132","author":"Rozen","year":"2000","journal-title":"Methods Mol Biol"}],"container-title":["Cancer Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article-pdf\/2\/1\/47\/1814008\/47.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article-pdf\/2\/1\/47\/1814008\/47.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,6]],"date-time":"2022-06-06T18:42:44Z","timestamp":1654540964000},"score":1,"resource":{"primary":{"URL":"https:\/\/aacrjournals.org\/cancerdiscovery\/article\/2\/1\/47\/3015\/Molecular-Ontogeny-of-Donor-Derived-Follicular"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,1,1]]},"references-count":28,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2012,1,12]]},"published-print":{"date-parts":[[2012,1,1]]}},"URL":"https:\/\/doi.org\/10.1158\/2159-8290.cd-11-0208","relation":{"has-preprint":[{"id-type":"doi","id":"10.1158\/2159-8290.22529091","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.c.6545853","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.22529088.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.22529079.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.22529103.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.22529085","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.22529097","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.22529097.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.22529073","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.22529100.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.22529091.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.22529094.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.22529103","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.c.6545853.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.22529076","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.22529088","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.22529094","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.22529082","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.22529073.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.22529076.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.22529079","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.22529100","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.22529085.v1","asserted-by":"object"},{"id-type":"doi","id":"10.1158\/2159-8290.22529082.v1","asserted-by":"object"}]},"ISSN":["2159-8274","2159-8290"],"issn-type":[{"value":"2159-8274","type":"print"},{"value":"2159-8290","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,1,1]]}}}